ArticleScientific reports2025
Identification of key biomarkers associated with necroptosis and immune infiltration in hepatitis B virus-related acute-on-chronic liver failure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pesticides Drive Liver Diseases Through Non-Apoptotic Regulated Cell Death Pathways.Diseases (Basel, Switzerland) · 2026Review
- The regulatory mechanisms and clinical translation potential of RNA-binding protein RALY in tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatitis B virus-related acute-on-chronic liver failure (ACHBLF) is a severe condition associated with short-term mortality without liver transplantation. Substantial evidence indicates that necroptosis and immune infiltration play critical roles in ACHBLF development. Therefore, the identification of necroptosis-related biomarkers may be beneficial for prognostic evaluations and may shed light on potential therapeutic targets for ACHBLF. In this study, we used integrated bioinformatics analysis and machine learning algorithms to investigate the correlation between necroptosis and immune infiltration using peripheral blood mononuclear cells from ACHBLF patients. First, after GSE168048 and GSE248217 were obtained from the Gene Expression Omnibus (GEO) database, differentially expressed genes (DEGs) between ACHBLF patients and normal controls were identified. With the help of the weighted gene coexpression network, 211 necroptosis-related DEGs were identified by intersecting the DEGs with necroptosis-related genes (NRGs). The functional characterization of these NRG-related DEGs was subsequently performed using GO, KEGG, and gene set enrichment analysis. Hub genes were identified through the integration of LASSO regression, support vector machines recursive feature elimination, and random forest. Immune-related functions were explored by analyzing the correlations between hub gene expression and immune cells infiltration. Furthermore, mRNA-miRNA-lncRNA interaction network, RNA-binding proteins (RBPs) and transcription factors were predicted using the miRDB, starBase and hTFtarget databases. Finally, target drugs were predicted using a connectivity map. A total of 7461 DEGs were identified between the ACHBLF and normal groups; 3123 genes were upregulated and 4338 genes were downregulated. A total of 211 NRG-related DEGs and 5 hub genes (FCRL3, CDC14A, KLHL22, RALY, and MAP4K1) were obtained. The hub genes were enriched in the T cell receptor signaling pathway, ubiquitin-mediated proteolysis, and the MAPK signaling pathway and were correlated with immune cell infiltration. A lncRNA XIST-miR-424-5p-CDC14A regulatory network was constructed, and 20RBPs and 2 transcription factors (GATA1 and CEBPB) were identified. In addition, 10 candidate drugs were predicted to target MAP4K1. The 5 hub genes could serve as biomarkers for predicting the prognosis of ACHBLF patients and provide clues for new potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.